Ignite Creation Date:
2024-05-06 @ 9:42 AM
Last Modification Date:
2024-10-26 @ 12:18 PM
Study NCT ID:
NCT03051256
Status:
COMPLETED
Last Update Posted:
2023-11-01
First Post:
2017-02-03
Brief Title:
Safety Tolerability PK Profile and Symptom Response of a 7-Day Dosing With 25 mg or 50 mg Daily of REL-1017 in MDD
Sponsor:
Organization:
Relmada Therapeutics Inc